USC Researchers Develop Method for Continuous In-Body Production of Cancer-Fighting Cells
Researchers at the University of Southern California have uncovered a method to produce an ongoing supply of cancer-fighting immune cells. The key innovation lies in targeting and modifying immature immune cells rather than mature ones, which allows the body to continuously generate enhanced tumor-fighting cells internally.
The approach differs from conventional CAR-T cell therapies, which require extracting, modifying, and reinfusing a patient's own mature T cells—a process that is resource-intensive and produces a finite number of treatment cells. By contrast, this new system leverages the body's natural cell production pathways to sustain a steady output of genetically engineered immune cells.
According to the research team, the engineered cells are designed both to attack cancer directly and to bolster the body's existing immune defenses. This dual capability could offer more robust and sustained anti-tumor responses.
The study represents an early but promising development in immunotherapy. Further research will be needed to evaluate the approach's safety, efficacy, and scalability in human patients.